Bausch + Lomb Launches Arise™ Orthokeratology Lens System in the United States
Bausch + Lomb (NYSE/TSX: BLCO) has launched Arise™, an innovative orthokeratology lens system in the United States. The system features intelligent cloud-based technology that streamlines the lens design process for treating myopia (nearsightedness).
The Arise platform includes the first FDA-approved orthokeratology lens design with toric peripheral curves for overnight myopia treatment. The system efficiently syncs with topographers to create precise lens designs in seconds, eliminating the need for fitting sets. Its advanced algorithms interpret corneal topography images instantly and include an overnight outcome map library for evaluating lens centration and patient progress.
This launch addresses a significant market need, as myopia affects approximately 28% of the global population (2 billion people), with projections showing an increase to 50% (5 billion people) by 2050. The platform is currently available in the United States, United Kingdom, and Europe.
Bausch + Lomb (NYSE/TSX: BLCO) ha lanciato Arise™, un innovativo sistema di lenti ortocheratologiche negli Stati Uniti. Il sistema è dotato di tecnologia intelligente basata su cloud che semplifica il processo di progettazione delle lenti per il trattamento della miopia (miopia).
La piattaforma Arise include il primo design di lenti ortocheratologiche approvato dalla FDA con curve periferiche toriche per il trattamento notturno della miopia. Il sistema si sincronizza efficientemente con i topografi per creare design di lenti precisi in pochi secondi, eliminando la necessità di set di adattamento. I suoi algoritmi avanzati interpretano istantaneamente le immagini della topografia corneale e includono una libreria di mappe di risultati notturni per valutare la centratura delle lenti e i progressi del paziente.
Questo lancio risponde a un'importante esigenza di mercato, poiché la miopia colpisce circa il 28% della popolazione globale (2 miliardi di persone), con proiezioni che mostrano un aumento al 50% (5 miliardi di persone) entro il 2050. La piattaforma è attualmente disponibile negli Stati Uniti, nel Regno Unito e in Europa.
Bausch + Lomb (NYSE/TSX: BLCO) ha lanzado Arise™, un innovador sistema de lentes de ortoqueratología en los Estados Unidos. El sistema cuenta con tecnología inteligente basada en la nube que optimiza el proceso de diseño de lentes para tratar la miopía (miopía).
La plataforma Arise incluye el primer diseño de lentes de ortoqueratología aprobado por la FDA con curvas periféricas tóricas para el tratamiento nocturno de la miopía. El sistema se sincroniza eficientemente con topógrafos para crear diseños de lentes precisos en segundos, eliminando la necesidad de juegos de adaptación. Sus algoritmos avanzados interpretan instantáneamente las imágenes de topografía corneal e incluyen una biblioteca de mapas de resultados nocturnos para evaluar la centración de las lentes y el progreso del paciente.
Este lanzamiento aborda una necesidad significativa en el mercado, ya que la miopía afecta aproximadamente al 28% de la población mundial (2 mil millones de personas), con proyecciones que muestran un aumento al 50% (5 mil millones de personas) para 2050. La plataforma está actualmente disponible en los Estados Unidos, el Reino Unido y Europa.
바우쉬 + 롬 (NYSE/TSX: BLCO)이 미국에서 혁신적인 각막 교정 렌즈 시스템인 Arise™를 출시했습니다. 이 시스템은 근시(근시) 치료를 위한 렌즈 설계 프로세스를 간소화하는 클라우드 기반의 지능형 기술을 특징으로 합니다.
Arise 플랫폼은 하룻밤 근시 치료를 위한 토릭 주변 곡선이 있는 최초의 FDA 승인 각막 교정 렌즈 디자인을 포함합니다. 이 시스템은 정밀한 렌즈 디자인을 몇 초 만에 생성하기 위해 토포그래퍼와 효율적으로 동기화되며, 적합 세트의 필요성을 없앱니다. 고급 알고리즘이 각막 지형 이미지를 즉시 해석하고 렌즈 중심 및 환자 진행 상황을 평가하기 위한 야간 결과 맵 라이브러리를 포함합니다.
이 출시로 인해 약 28%의 전 세계 인구(20억 명)가 근시의 영향을 받으며, 2050년까지 50% (50억 명)로 증가할 것으로 예상되는 중요한 시장 요구를 해결합니다. 이 플랫폼은 현재 미국, 영국 및 유럽에서 사용 가능합니다.
Bausch + Lomb (NYSE/TSX: BLCO) a lancé Arise™, un système de lentilles d'orthokératologie innovant aux États-Unis. Le système dispose d'une technologie intelligente basée sur le cloud qui rationalise le processus de conception des lentilles pour traiter la myopie (myopie).
La plateforme Arise comprend le premier design de lentilles d'orthokératologie approuvé par la FDA avec des courbes périphériques toriques pour le traitement nocturne de la myopie. Le système se synchronise efficacement avec des topographes pour créer des designs de lentilles précis en quelques secondes, éliminant ainsi le besoin de jeux d'adaptation. Ses algorithmes avancés interprètent instantanément les images de topographie cornéenne et incluent une bibliothèque de cartes de résultats nocturnes pour évaluer la centration des lentilles et les progrès des patients.
Ce lancement répond à un besoin de marché significatif, la myopie touchant environ 28 % de la population mondiale (2 milliards de personnes), avec des projections montrant une augmentation à 50 % (5 milliards de personnes) d'ici 2050. La plateforme est actuellement disponible aux États-Unis, au Royaume-Uni et en Europe.
Bausch + Lomb (NYSE/TSX: BLCO) hat Arise™, ein innovatives Orthokeratologie-Linsensystem in den Vereinigten Staaten, eingeführt. Das System verfügt über intelligente cloudbasierte Technologie, die den Linsendesignprozess zur Behandlung von Myopie (Kurzsichtigkeit) optimiert.
Die Arise-Plattform umfasst das erste von der FDA zugelassene Orthokeratologie-Linsendesign mit torischen Randkurven zur nächtlichen Behandlung von Myopie. Das System synchronisiert sich effizient mit Topografen, um präzise Linsendesigns in Sekunden zu erstellen und die Notwendigkeit von Anpassungssets zu beseitigen. Seine fortschrittlichen Algorithmen interpretieren die Bilder der Hornhauttopografie sofort und beinhalten eine Bibliothek von Nacht-Ergebniskarten zur Bewertung der Linsen-Zentrierung und des Patientenfortschritts.
Mit diesem Launch wird ein bedeutender Marktbedarf adressiert, da Myopie etwa 28% der Weltbevölkerung (2 Milliarden Menschen) betrifft, mit Prognosen, die einen Anstieg auf 50% (5 Milliarden Menschen) bis 2050 zeigen. Die Plattform ist derzeit in den Vereinigten Staaten, im Vereinigten Königreich und in Europa verfügbar.
- First FDA-approved orthokeratology lens design with toric peripheral curves
- Addresses growing market with myopia affecting 28% of global population
- Cloud-based platform enables remote access and expert consultation support
- Streamlined process reduces practitioner chair time and increases efficiency
- Requires specific safety protocols and carries risk of ulcerative keratitis
- to treating myopia up to 5.00 diopters with astigmatism up to 1.50 diopters
Insights
Bausch + Lomb's launch of the Arise orthokeratology system represents a strategic expansion in the high-growth myopia management market. This cloud-based platform streamlines the complex lens fitting process, potentially increasing adoption rates among eye care professionals less experienced with orthokeratology.
The market opportunity is substantial with myopia affecting 28% of the global population, projected to reach 50% by 2050. This represents an expanding addressable market from 2 billion to 5 billion potential patients. The overnight myopia treatment segment is particularly attractive due to premium pricing and recurring revenue potential from lens replacements.
What sets Arise apart is its first-to-market FDA approval for orthokeratology lenses with toric peripheral curves, establishing a competitive advantage in treating astigmatic myopia patients. The cloud-based architecture also creates operational efficiencies while building recurring revenue through potential subscription models.
While the immediate revenue impact remains unquantified, this launch strengthens Bausch + Lomb's overall vision care portfolio. Myopia management represents one of the fastest-growing segments in eye care, and this technology-enabled solution positions the company well against competitors focusing solely on traditional contact lenses or glasses.
The Arise system demonstrates Bausch + Lomb's evolution toward digitally-enhanced medical devices with its cloud-based, algorithm-driven approach. The platform represents a significant technological advancement in orthokeratology by automating the complex lens design process that traditionally requires substantial expertise and time.
From a technical perspective, the system's direct integration with topographers creates a seamless digital workflow - capturing 3D eye images, processing them through proprietary algorithms, and automatically generating precise lens designs in seconds. This eliminates the traditional fitting sets while maintaining or potentially improving clinical outcomes.
The cloud architecture offers two substantial advantages beyond the clinical benefits: remote access to patient data for practitioners and the ability for Bausch + Lomb to provide expert consultation support remotely. This creates a continuous feedback loop for product improvement while gathering valuable real-world data across markets.
For practitioners, the efficiency gains from reduced chair time translate directly to practice profitability. The system's accessibility to less experienced practitioners could significantly expand the addressable market for orthokeratology, which has historically been to specialists with extensive training. By lowering this barrier to entry, Bausch + Lomb is potentially expanding both the practitioner and patient base for this treatment modality.
Myopia, or nearsightedness, is one of the most common ocular disorders worldwide and a leading cause of visual impairment in children.1 Studies predict the global prevalence of myopia will rise from
“Traditional orthokeratology lens fitting methods can be complex and time-consuming,” said Yang Yang, president, Global Vision Care, Bausch + Lomb. “The Arise platform’s streamlined fitting process will reduce chair time† and increase efficiency for eye care professionals.”
Engineered for precision and speed, Arise uses advanced algorithms to instantly interpret corneal topography images and recommend lens designs in seconds – no fitting set required. It is designed for lens fitters of all experience levels and efficiently evaluates lens centration and patient progress using its overnight outcome map library, recommending adjustments following overnight wear, if needed. Additionally, the cloud-based platform allows secure access to patient data from anywhere and direct support from the Bausch + Lomb expert consultation team.
“Arise combines all aspects of the orthokeratology process—from topography capture to lens design and more—into one seamless, user-friendly technology,” said Brooke Messer, OD, FAAO, FSLS, Vance Thompson Vision,
Arise is now commercially available in
*Based on clinical study data
INDICATIONS FOR USE
Boston Orthokeratology (oprifocon A) shaping lenses for overnight wear are indicated for use in the reduction of myopic refractive error in non-diseased eyes. The lenses are indicated for overnight wear as part of the Bausch + Lomb Vision Shaping Treatment VST® process for the temporary reduction of myopia up to 5.00 diopters with eyes having astigmatism up to 1.50 diopters. The lenses may only be disinfected using a chemical disinfection system.
SAFETY INFORMATION CONTRAINDICATIONS
DO NOT USE the Boston Orthokeratology (oprifocon A) shaping lenses when any of the following conditions exist:
- Acute and sub-acute inflammations or infection of the anterior chamber of the eye
- Any eye disease, injury, or abnormality that affects the cornea, conjunctiva, or eyelids
- Severe insufficiency of tears (dry eyes)
- Corneal hypoesthesia (reduced corneal sensitivity)
- Any systemic disease which may affect the eye or be exacerbated by wearing contact lenses
- Allergic reactions of ocular surfaces or adnexa which may be induced or exaggerated by wearing contact lenses or use of contact lens solutions
- Allergy to any ingredient, such as mercury or thimerosal, in a solution which is to be used to care for your Boston Orthokeratology (oprifocon A) shaping lenses
- Any active corneal infection (bacterial, fungal, or viral)
- If eyes become red or irritated
WARNINGS
The risk of ulcerative keratitis has been shown to be greater among wearers of extended wear lenses than among wearers of daily wear lenses. The risk among extended wear use users increases the number of consecutive days that lenses are worn between removals, beginning with the first overnight use. Smoking increases the risk of ulcerative keratitis for contact lens wearers. Wearing the lenses continuously (extended wear) presents increased risk, which increases with the number of consecutive days the lenses are worn between removals. Although the safety risks of overnight wear with removal upon wakening may not be as great as with extended wear, there is still increased risk beginning with the first overnight period.
PRECAUTIONS
When selecting an appropriate lens design and parameters, the eye care practitioner should consider all factors that affect lens performance and the patient’s ocular health; including oxygen permeability, wettability, central and peripheral thickness, and optic zone diameter.
ADVERSE EVENTS
A total of 378 eyes (191 patients) were enrolled in a clinical study. There were twelve significant lens-related adverse events reported in ten subjects. All eyes that showed acuity reductions were documented as returning to normal vision, except two eyes of one subject with severe corneal staining that showed ≥2 lines loss of BSCVA. The return to pre-treatment VA was not recorded for this subject, although the subject returned to soft contact lens wear and verbally reported that vision was normal. All adverse events resolved without further complications. A separate clinical study evaluated the effect of non-spherical (toric) peripheral curves on 45 astigmatic patients who were orthokeratology lens-naïve. Among the dispensed subjects, no significant adverse events were reported.
ATTENTION: Refer to the package insert for a complete listing of indications, warnings and precautions, clinical trial information, etc.
CAUTION: Federal (
About Orthokeratology
Orthokeratology, or ortho-k, is a non-surgical procedure that is primarily used to correct nearsightedness (myopia). It uses specially designed contact lenses to temporarily reshape the cornea and improve vision. The lenses are worn overnight to gradually correct the shape of the cornea, allowing the eyes to focus light more effectively onto the retina.
About Bausch + Lomb
Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in
†Based on survey results from 13 eye care professionals who accessed and utilized the system.
References:
1 Lipson MJ. Contemporary Orthokeratology. 2019.
2 Holden BA, Fricke TR, Wilson DA, et al. Global Prevalence of Myopia and High Myopia and Temporal Trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036–42.
© 2025 Bausch + Lomb.
ARI.0025.USA.25
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317590054/en/
Media Contact:
Kristy Marks
kristy.marks@bausch.com
(908) 927-0683
Investor Contact:
George Gadkowski
george.gadkowski@bausch.com
(877) 354-3705 (toll free)
(908) 927-0735
Source: Bausch + Lomb Corporation
FAQ
What is the main feature of Bausch + Lomb's (BLCO) new Arise™ lens system?
How does the Arise™ system improve the orthokeratology fitting process for BLCO customers?
What makes BLCO's Arise™ orthokeratology lenses unique in the market?
Where is Bausch + Lomb's (BLCO) Arise™ system currently available?
